Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.46 -1.35%
EPS Growth %: +23.5%
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +23.5%
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
